뉴스벤징가
Evommune's Skin Disorder Study Falls Short
· 발표
기사 요약
Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.
기사 원문에서 발췌했어요.Evommune said EVO756 failed to meet the primary endpoint in a Phase 2b CSU trial, ending development in the indication.
기사 원문에서 발췌했어요.
댓글 —
댓글을 불러오고 있어요…